人血清半胱氨酸蛋白酶抑制剂S与结直肠癌的相关性研究.pdfVIP

摘要 目的：探讨人血清半胱氨酸蛋白酶抑制剂S （CST4）与结直肠癌的相关性，为进一步指导临床辅助 诊断结直肠癌可能提供一定的参考。 方法：选取自2018年 10 月至2019年3 月就诊于石河子大学医学院第一附属医院符合要求的患者， 根据肠镜 （及病理诊断）结果将其分为结直肠癌组、结直肠腺瘤组及健康对照组；分别收集各组患 者的CEA、CA199、CA724 等临床资料，并采集各组观察对象的血液样本，平行检测各组血清样本 的CST4 含量，应用受试者工作特征(ROC)曲线计算以CST4 为检测指标的结直肠癌的诊断阈值，并 计算上述指标对结直肠癌进行辅助诊断的灵敏度、特异度等统计学指标，对比分析得出结论。 结果：结直肠癌组的CST4 检测结果显著高于健康对照组，差异有统计学意义(P 0.017)；CST4 诊 断结直肠癌的ROC 曲线下面积 （AUC）为0.718，CST4 的ELISA 检测系统对于结直肠癌诊断的阈 值为90.29U/mL 时，灵敏度为88.2%，特异度为48.0%；结直肠癌组CEA、CA199、CA724 检测结 果明显高于结直肠腺瘤组及健康对照组，差异有统计学意义(P 0.017)；血清CST4 和CEA、CA199、 CA724 联合检测诊断结直肠癌的灵敏度为94.1%，特异度为36.0%，即四者联合可以显著提高诊断 结直肠癌的能力(P 0.05)。 结论：结直肠癌患者中血清半胱氨酸蛋白酶抑制剂S含量较高，两者存在相关性，其作为新型血液 生物标志物在结直肠癌的临床诊断价值方面具有一定的潜力。血清半胱氨酸蛋白酶抑制剂S与CEA、 CA199、CA724 联合检测可提高结直肠癌诊断的敏感性。 关键词：结直肠癌；半胱氨酸蛋白酶抑制剂S；相关性 I Abstract Objective: To investigate the correlation between human serum cystatin S(CST4) and colorectal cancer, which mayprovide somereferencefor further guidanceofclinical assistant diagnosisofcolorectal cancer. Methods: Patients who met the requirements in the First Affiliated Hospital of Medical school of Shihezi University from October 2018 to March 2019 were collected and divided into colorectal cancer group, colorectal adenoma group and healthy control group based on colonoscopy and pathological results. CEA, CA199, CA724 and other clinical data and blood samples were collected from each group of observation objects, and the CST4 content of serum samples from each group was measured in parallel. The receiver operating characteristic (ROC) curve was used to calculate the diagnostic threshold of colorectal cancer with CST4 as the detection index. And the sensitivity, specificity and other statistical indicators of colorectalcancer for auxiliary diagnosiswerecalculated,compared andanalyzed. Results: The CST4 test results in the colorectal cancer group were significantly higher than